Kura Oncology, Inc.
KURA
$5.95
$0.223.84%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -73.82% | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -73.82% | -- | |||
| Cost of Revenue | -63.97% | -- | |||
| Gross Profit | 58.74% | -- | |||
| SG&A Expenses | -5.13% | 32.41% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 3.24% | 27.48% | |||
| Operating Income | -188.13% | 62.50% | |||
| Income Before Tax | -232.59% | 68.39% | |||
| Income Tax Expenses | -88.80% | -- | |||
| Earnings from Continuing Operations | -198.84% | 64.68% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -198.84% | 64.68% | |||
| EBIT | -188.13% | 62.50% | |||
| EBITDA | -189.69% | 62.71% | |||
| EPS Basic | -197.96% | 64.76% | |||
| Normalized Basic EPS | -87.96% | 44.36% | |||
| EPS Diluted | -197.96% | 64.76% | |||
| Normalized Diluted EPS | -87.96% | 44.36% | |||
| Average Basic Shares Outstanding | 0.32% | 0.21% | |||
| Average Diluted Shares Outstanding | 0.32% | 0.21% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||